
Imugene (ASX: IMU) surged over 35% after early Azer-cel trial results showed strong response rates in blood cancer patients, reigniting biotech speculation. Despite the rally, the stock remains highly volatile and pre-revenue, with future moves dependent on clinical progress, funding needs, and upcoming ASCO updates.